Late stage pipeline

Focus on Innovation and Science to unlock mid-term potential

Pipeline updated as of January 2025

Molecule name Indication Phase I Phase II Phase III Under Registration Geography
Recent approvals
Efinaconazole
Onychomycosis
100 Under registration
EU
Life-cycle management (label extension)
Sarecycline
Acne
92 Under registration
China
Tirbanibulin
Actinic keratosis (LF)
70 Fase3
EU
Tildrakizumab
Psoriatic arthritis
70 Fase3
EU
Lebrikizumab
Atopic Dermatitis pediatric
70 Fase3
EU
NMEs
Anti-IL-21 mAb
Inflammatory skin disease
24 Phase 1
Worldwide
Anti-IL-1RAP mAb
Hidradenitis Suppurativa
20 Phase 1
Worldwide
IL-2muFc
Inflammatory skin disease
12 Phase 1
Worldwide *
ZKN-013
Rare Dermatology (RDEB/JEB)
8 Phase 1
Worldwide

Onychomycosis Efinaconazole Under registration EU

Acne Sarecycline Under registration china

Actinic keratosis (LF) Tirbanibulin Fase3 EU

Psoriatic arthritis Tildrakizumab Fase3 EU

Atopic Dermatitis pediatric Lebrikizumab Fase3 EU

Inflammatory skin disease Anti-IL-21 mAb Phase 1 worldwide

Hidradenitis Suppurativa Anti-IL-1RAP mAb Phase 1 worldwide

Inflammatory skin disease IL-2muFc Phase 1 worldwide_exchina ‏‏* Worldwide ex-Greater China

Rare Dermatology (RDEB/JEB) ZKN-013 Phase 1 worldwide